UNSPSC 51434901: Amlodipine/valsartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434901 Amlodipine/valsartan is a Commodity code covering prescription and over-the-counter medications supplied to state and local health systems, emergency services, and health-benefit programs. State and local governments procure under this code when sourcing specific branded or generic pharmaceuticals for fire-rescue paramedics, hospital pharmacies, managed-care formularies, and employee health plans. Issuing bodies include city purchasing departments (such as the City of Tampa), state health and human services agencies (such as the Texas HHS Commission), and multistate cooperative purchasing alliances (such as the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work ranges from single-medication line-item buys for emergency medical services to broad generic-pharmaceutical framework agreements serving multiple state and local jurisdictions across wholesale channels.

The code shows activity across Florida, Texas, and Minnesota, with a multistate footprint through cooperative purchasing vehicles. Recent opportunities include the City of Tampa's sealed-bid procurement (IFB 26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise bid discount; the Minnesota Multistate Cooperative Purchasing Alliance's Request for Proposal (RFP S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, covering participating state and local facilities across Minnesota and Oregon with a two-year contract term and 3 percent administrative-fee requirement; and the Texas Health and Human Services Commission's Request for Information (RFI HHS0017013) issued April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, representing exploratory procurement activity ahead of a formal RFP. Cooperative purchasing vehicles expand geographic reach and allow smaller vendors to serve multiple jurisdictions under single framework agreements.